Floatz logo

52 assets in Lung Neoplasm

Therapeutic assets addressing Lung Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carboplatin
Lung Neoplasm
Nanfang Hospital, Southern Medical UniversityP4BB (69)
Cyclophosphamide
Lung Neoplasm
PfizerP3BB (64)
Cis-Diamminedichloroplatinum Ii
Lung Neoplasm
Nanfang Hospital, Southern Medical UniversityP3B (62)
Trastuzumab
Lung Neoplasm
Cancer Research UKP2/3B (62)
Docetaxel
Lung Neoplasm
Merck Sharp & Dohme LLCP3B (61)
Osimertinib
Lung Neoplasm
Jin YingP2B (61)
Pembrolizumab
Lung Neoplasm
Sarah GoldbergP3B (61)
Nogitecan
Lung Neoplasm
GlaxoSmithKlineP3B (60)
Ris-Rez
Lung Neoplasm
GlaxoSmithKlineP3B (60)
Endostatin
Lung Neoplasm
The First People's Hospital of LianyungangP3B (59)
Olaparib
Lung Neoplasm
Merck Sharp & Dohme LLCP3B (59)
Durvalumab
Lung Neoplasm
Latin American Cooperative Oncology GroupP3B (58)
Etoposide
Lung Neoplasm
PfizerP3B (58)
Fludarabine
Lung Neoplasm
PfizerP2B (57)
Pertuzumab
Lung Neoplasm
Cancer Research UKP2/3B (57)
Adriamycin
Lung Neoplasm
Actuate Therapeutics Inc.P2CCC (53)
Catequentinib
Lung Neoplasm
The First Affiliated Hospital of Xinxiang Medical CollegeP2CCC (53)
I-Dxd
Lung Neoplasm
Merck Sharp & Dohme LLCP2CCC (53)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cdh6(Cadherin 6, K-Cadherin (Foetal Kidney), Cadherin 6 Type 2)], Humanized Monoclonal Antibody Conjugated To Deruxtecan, Comprising A Linker And A Camptothecin Derivative
Lung Neoplasm
Merck Sharp & Dohme LLCP2CCC (53)
Irinotecan
Lung Neoplasm
Actuate Therapeutics Inc.P2CCC (53)
Lomustine
Lung Neoplasm
Actuate Therapeutics Inc.P2CCC (53)
Niraparib
Lung Neoplasm
Tempus AIP2CCC (53)
esg401
Lung Neoplasm
Shanghai Escugen Biotechnology Co., LtdP1/2CCC (52)
Adebrelimab
Lung Neoplasm
Nanfang Hospital, Southern Medical UniversityP2CCC (51)
Brigimadlin
Lung Neoplasm
Boehringer IngelheimP2CCC (51)
Dexasone
Lung Neoplasm
Brown UniversityP2CCC (51)
Envafolimab
Lung Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP2CCC (51)
Hydroxychloroquine
Lung Neoplasm
Henan Cancer HospitalP2CCC (51)
pf-08634404
Lung Neoplasm
PfizerP2CCC (51)
Teniposide
Lung Neoplasm
Shanghai Pulmonary Hospital, Shanghai, ChinaP2CCC (51)
Vebreltinib
Lung Neoplasm
Shanghai Chest HospitalP2CCC (51)
Elraglusib
Lung Neoplasm
Actuate Therapeutics Inc.P2CCC (50)
Sitravatinib
Lung Neoplasm
Sarah GoldbergP2CCC (49)
Opnurasib
Lung Neoplasm
Novartis PharmaceuticalsP1/2CCC (48)
Tislelizumab
Lung Neoplasm
Novartis PharmaceuticalsP1/2CCC (48)
Star0602
Lung Neoplasm
Marengo Therapeutics, Inc.P1/2CC (47)
tno155
Lung Neoplasm
Novartis PharmaceuticalsP1/2CC (45)
Atezolizumab
Lung Neoplasm
Cancer Research UKP1/2CC (43)
Blu-701
Lung Neoplasm
Blueprint Medicines CorporationP1CC (43)
htl0039732 capsules
Lung Neoplasm
Cancer Research UKP1/2CC (43)
Ksq-001Ex
Lung Neoplasm
M.D. Anderson Cancer CenterP1/2CC (43)
JYP0322
Lung Neoplasm
Guangzhou JOYO Pharma Co., LtdP1C (39)
Tnhyp217 Car T Cells
Lung Neoplasm
National Cancer Institute (NCI)P1C (39)
Anti-Pd-L1 Monoclonal Antibody Ck-301
Lung Neoplasm
Checkpoint Therapeutics, Inc.P1C (38)
[18f]f-resca-epcd6
Lung Neoplasm
RenJi HospitalN/AD (30)
[18f]f-resca-rt4
Lung Neoplasm
RenJi HospitalN/AD (30)
[18F]F-RESCA-T4
Lung Neoplasm
RenJi HospitalN/AD (30)
[68ga]ga-nota-epcd6
Lung Neoplasm
RenJi HospitalN/AD (30)
[68ga]ga-nota-rt4
Lung Neoplasm
RenJi HospitalN/AD (30)
[68ga]ga-nota-t4
Lung Neoplasm
RenJi HospitalN/AD (30)
Showing 1 to 50 of 52 assets
PreviousPage 1 of 2Next